Clinical Significance of Serum Interleukin-31 and Interleukin-33 Levels in Patients of Endometrial Cancer: A Case Control Study

Table 3

Correlations of serum IL-31 and IL-33 levels with clinical factors in patients with EC (pg/mL). Data is shown as mean ± standard deviation (SD).

Characters	Number of patients (%)	Serum IL-31	value	Serum IL-33	value
Age (years)
<60	108 (67.5%)	170.87 ± 33.05	0.335	110.36 ± 7.69	0.062
≥60	52 (32.5%)	181.37 ± 29.11		105.73 ± 7.70
BMI
18.5 ≤ BMI ≤ 24.99	72 (45%)	162.76 ± 37.98	0.859	108.11 ± 8.36	0.818
25 ≤ BMI ≤ 28	68 (42.5%)	169.85 ± 38.89		109.71 ± 6.77
BMI > 28	20 (12.5%)	163 ± 50.57		108.6 ± 6.6
Tumor stages
S1 and S2	88 (55%)	164.18 ± 22.09	0.024	106.66 ± 6.27	0.035
S3 and S4	72 (45%)	186.63 ± 37.80		111.54 ± 7.88
Depth of invasion
T1 and T2	108 (67.5%)	169.04 ± 29.38	0.182	106.53 ± 6.27	0.008
T3 and T4	52 (32.5%)	183.01 ± 34.84		112.72 ± 7.62
Lymph node metastasis
Absent	124 (77.5%)	169.86 ± 27.08	0.104	107.50 ± 4.45	0.029
Present	36 (22.5%)	189.52 ± 37.85		113.52 ± 9.27
Distant metastasis
M0	120 (75%)	169.50 ± 29.51	0.100	107.24 ± 6.20	0.014
M1	40 (25%)	188.63 ± 35.80		113.71 ± 8.76

value means the results of IL-31 with the clinical factors.
value means the results of IL-33 with the clinical factors.